Hi, I am Robert Fruscio, My LiveDNA is 39.6451
 
   
  Home
 
 
 
Dr. Robert Fruscio
 
Highest Degree: Ph.D. in Gynecologic Oncology from University of Milan Bicocca, Italy
 
Institute: Istituto Di Ricerche Farmacologiche Mario Negri, Italy
 
Area of Interest: Biomedical Sciences
  •   Oncology
  •   Obstetrics
  •   Gynaecology
  •   Ultrasound
 
URL: http://livedna.org/39.6451
 
My SELECTED Publications
1:   Anna, T.D., M. Signorelli, P. Benedetti-Panici, A. Maggioni and R. Fossati et al., 2012. Systematic lymphadenectomy in ovarian cancer at second-look surgery: A randomised clinical trial. Br. J. Cancer, 107: 785-792.
CrossRef  |  Direct Link  |  
2:   Assi, F., R. Fruscio, C. Bonardi, A. Ghidini, P. Allavena, A. Mantovani and A. Locatelli, 2007. Pentraxin 3 in plasma and vaginal fluid in women with preterm delivery. BJOG: Int. J. Obstetrics Gynaecol., 114: 143-147.
CrossRef  |  
3:   Boussios, S., S.N. Han, R. Fruscio, M.J. Halaska and P.B. Ottevanger, et al., 2013. Lung cancer in pregnancy: Report of nine cases from an international collaborative study. Lung Cancer, 82: 499-505.
CrossRef  |  PubMed  |  Direct Link  |  
4:   Buda, A., P.L. Confalonieri, L.C. Rovati, R. Fruscio and D. Giuliani et al., 2012. Better anatomical and cosmetic results using tunneled lotus petal flap for plastic reconstruction after demolitive surgery for vulvar malignancy. Int. J. Gynecol. Can., 22: 860-864.
5:   Buda, A., R. Fruscio, C. Pirovano, R. Milani, M. Signorelli and M. Betti, 2012. The use of TachoSil for the prevention of postoperative complications after groin dissection in cases of gynecologic malignancy. Int. J. Gynaecol. Obstet., 117: 217-219.
CrossRef  |  PubMed  |  
6:   Caiola, E., E. Rulli, R. Fruscio, A. Buda, M. Broggini and M. Marabese, 2012. KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer. Am. J. Cancer. Res., 2: 298-308.
Direct Link  |  
7:   Caiola, E., L. Porcu, R. Fruscio, D. Giuliani and R. Milani et al., 2013. DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer. Pharmacog. J., 13: 159-172.
PubMed  |  Direct Link  |  
8:   Calura, E., R. Fruscio, L. Paracchini, E. Bignotti and A. Ravaggi et al., 2013. MiRNA landscape in Stage I Epithelial Ovarian Cancer defines the histotype specificities. Clin. Cancer Res., 19: 4114-4123.
Direct Link  |  
9:   Crivellaro, C., M. Signorelli, L. Guerra, E. De Ponti and A. Buda et al., 2012. 18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer. Gynecol. Oncol., 127: 131-135.
CrossRef  |  PubMed  |  Direct Link  |  
10:   Crivellaro, C., M. Signorelli, L. Guerra, E. de Ponti and C. Pirovano et al., 2013. Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: The role of 18F-FDG PET/CT. Gynecol. Oncol., 130: 306-311.
CrossRef  |  PubMed  |  Direct Link  |  
11:   D'Incalci, M., E. Erba, G. Damia, E. Galliera and L. Carrassa et al., 2002. Unique features of the mode of action of ET-743. Oncologist, 7: 210-216.
CrossRef  |  
12:   Daemen, A., D. Jurkovic, C. van Holsbeke, S. Guerriero and A.C. Testa et al., 2011. Effect of cancer prevalence on the use of risk‐assessment cut‐off levels and the performance of mathematical models to distinguish malignant from benign adnexal masses. Ultrasound Obstetrics Gynecol., 37: 226-231.
CrossRef  |  
13:   Daemen, A., L. Valentin, R. Fruscio, C. van Holsbeke and G.B. Melis et al., 2011. Improving the preoperative classification of adnexal masses as benign or malignant by second-stage tests. Ultrasound Obstetrics Gynecol., 37: 100-106.
CrossRef  |  PubMed  |  
14:   Fadini, R., M. Dal Canto, M.M. Renzini, R. Milani and R. Fruscio et al., 2012. Embryo transfer following in vitro maturation and cryopreservation of oocytes recovered from antral follicles during conservative surgery for ovarian cancer. J. Assist. Reprod. Genet., 29: 779-781.
CrossRef  |  PubMed  |  
15:   Franchi, D., S. Boveri, R. Fruscio, D. Fischerova and S. Guerriero et al., 2013. Imaging in gynecological disease (8): Ultrasound characteristics of recurrent borderline ovarian tumors. Ultrasound Obstet. Gynecol., 14: 452-458.
CrossRef  |  PubMed  |  Direct Link  |  
16:   Fruscio, R., A. Garbi, G. Parma, A.A. Lissoni and D. Garavaglia et al., 2011. Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer. J. Nat. Cancer Inst., 103: 347-351.
CrossRef  |  
17:   Fruscio, R., A. Villa, S. Chiari, P. Vergani and L. Ceppi et al., 2012. Delivery delay with neoadjuvant chemotherapy for cervical cancer patients during pregnancy: a series of nine cases and literature review. Gynecol Oncol., 126: 192-197.
CrossRef  |  PubMed  |  
18:   Fruscio, R., A.A. Lissoni, R. Frapolli, S. Corso, C. Mangioni, M. D'Incalci and M. Zucchetti, 2006. Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients. Cancer Chemotherapy Pharmacol., 58: 319-325.
CrossRef  |  
19:   Fruscio, R., F. Padula, E. Mancini, A. Pellegrino and M. De Nictolis, 2008. Malignant transformation of vaginal endometriosis treated with neoadjuvant chemotherapy and surgery. J. Obstetrics Gynaecol. Res., 34: 706-708.
CrossRef  |  
20:   Fruscio, R., F. Sina, C. Dolci, M. Signorelli and C. Crivellaro et al., 2013. Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer. Gynecol. Oncol., 131: 689-693.
CrossRef  |  PubMed  |  Direct Link  |  
21:   Fruscio, R., N. Colombo, A.A. Lissoni, A. Garbi and R. Fossati et al., 2008. A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: Long-term survival analysis. Br. J. Cancer, 98: 720-727.
CrossRef  |  
22:   Fruscio, R., S. Corso, L. Ceppi, D. Garavaglia and A. Garbi et al., 2013. Conservative management of early-stage epithelial ovarian cancer: Results of a large retrospective series. Ann. Oncol., 24: 138-144.
CrossRef  |  
23:   Ganzinelli, M., P. Mariani, D. Cattaneo, R. Fossati and R. Fruscio et al., 2011. Expression of DNA repair genes in ovarian cancer samples: Biological and clinical considerations. Eur. J. Cancer, 47: 1086-1094.
CrossRef  |  
24:   Han, S.N., V.I. Kesic, K. Van Calsteren, S. Petkovic, F. Amant and ESGO, 2013. Cancer in pregnancy: A survey of current clinical practice. Eur. J. Obstet. Gynecol. Reprod. Biol., 167: 18-23.
CrossRef  |  PubMed  |  Direct Link  |  
25:   Kieran, M.W., J.G. Supko, D. Wallace, R. Fruscio and T.Y. Poussaint et al., 2009. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatric Blood Cancer, 52: 169-176.
CrossRef  |  
26:   Lissoni, A.A., F. Fei, R. Rossi, R. Fruscio, A. Villa and G. Zani, 2003. Ifosfamide in the treatment of malignant epithelial ovarian tumors. Oncology, 65: 59-62.
CrossRef  |  
27:   Lissoni, A.A., N. Colombo, A. Pellegrino, G. Parma and P. Zola et al., 2009. A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: The Snap-02 Italian collaborative study. Ann. Oncol., 20: 660-665.
CrossRef  |  PubMed  |  
28:   Manzoni, M., F. Pagni, P. Perego, R. Fruscio and S. Zaccone, 2013. Large polyp of the small intestine: An unexpected metastasis of ovarian carcinosarcoma. Int. J. Surg. Pathol., 21: 506-507.
Direct Link  |  
29:   Marchini, S., D. Cavalieri, R. Fruscio, E. Calura and D. Garavaglia et al., 2011. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: A retrospective study of two independent tumour tissue collections. Lancet Oncol., 12: 273-285.
CrossRef  |  
30:   Marchini, S., E. Poynor, R.R. Barakat, L. Clivio and M. Cinquini et al., 2012. The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer. Clin. Cancer res., 18: 4313-4324.
CrossRef  |  
31:   Marchini, S., M. Marabese, E. Marrazzo, P. Mariani and D. Cattaneo et al., 2008. Broggini M ıNp63 expression is associated with poor survival in ovarian cancer. Ann. Oncol., 19: 501-507.
32:   Marchini, S., P. Mariani, G. Chiorino, E. Marrazzo and R. Bonomi et al., 2008. Analysis of gene expression in early-stage ovarian cancer. Clin. Cancer Res., 14: 7850-7860.
CrossRef  |  
33:   Marchini, S., R. Fruscio, L. Clivio, L. Beltrame and L. Porcu et al., 2013. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur. J. Cancer, 49: 520-530.
CrossRef  |  PubMed  |  Direct Link  |  
34:   Milani, R., M.C. Cesana, F. Spelzini, M. Sicuri, S. Manodoro and R. Fruscio, 2013. Iliococcygeus fixation or abdominal sacral colpopexy for the treatment of vaginal vault prolapse: A retrospective cohort study. Int. Urogynecol. J., Vol. 13. .
PubMed  |  Direct Link  |  
35:   Mosig, R.A., L. Lin, E. Senturk, H. Shah and F. Huang et al., 2012. Application of RNA-Seq transcriptome analysis: CD151 is an Invasion/Migration target in all stages of epithelial ovarian cancer. J. Ovarian Res., Vol. 5. .
Direct Link  |  
36:   Mosig, R.A., M. Lobl, E. Senturk, H. Shah and S. Cohen et al., 2012. IGFBaP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer. J. Ovarian Res., Vol. 5. .
PubMed  |  Direct Link  |  
37:   Parikh, A., C. Lee, P. Joseph, S. Marchini and A. Baccarini et al., 2014. MicroRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat. Commun., Vol. 5. 10.1038/ncomms3977.
CrossRef  |  
38:   Pellegrino, A., A. Villa, R. Fruscio, M. Signorelli, M.G. Meroni, N. Ieda and D. Vitobello, 2008. Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in early stage cervical cancer. Surg Laparosc Endosc Percutan Tech., 18: 474-478.
CrossRef  |  PubMed  |  
39:   Pellegrino, A., E. Vizza, R. Fruscio, A. Villa and G. Corrado et al., 2009. Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in patients with Ib1 stage cervical cancer: Analysis of surgical and oncological outcome. Eur. J. Surgical Oncol., 35: 98-103.
CrossRef  |  
40:   Pellegrino, A., M. Signorelli, R. Fruscio, A. Villa and A. Buda et al., 2009. Feasibility and morbidity of total laparoscopic radical hysterectomy with or without pelvic limphadenectomy in obese women with stage I endometrial cancer. Arch. Gynecol. Obstetrics, 279: 655-660.
CrossRef  |  
41:   Pellegrino, A., R. Fruscio, A. Maneo, S. Corso, M. Battistello, V. Chiappa and M. Stomati, 2008. Harmonic scalpel versus conventional electrosurgery in the treatment of vulvar cancer. Int. J. Gynecol. Obstetrics, 103: 185-188.
CrossRef  |  
42:   Polato, F., A. Codegoni, R. Fruscio, P. Perego and C. Mangioni et al., 2005. PRL-3 phosphatase is implicated in ovarian cancer growth. Clin. Cancer Res., 11: 6835-6839.
CrossRef  |  
43:   Ricci, F., S. Bernasconi, L. Porcu, E. Erba and N. Panini et al., 2013. ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. Am. J. Cancer Res., 3: 221-229.
PubMed  |  Direct Link  |  
44:   Ricci, F., S. Bernasconi, P. Perego, M. Ganzinelli and G. Russo et al., 2012. Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype. Cell Cycle, Cell Cycle, 11: 1966-1966.
PubMed  |  Direct Link  |  
45:   Signorelli, M., L. Guerra, C. Pirovano, C. Crivellaro and R. Fruscio et al., 2013. Detection of nodal metastases by 18F-FDG PET/CT in apparent early stage ovarian cancer: A prospective study. Gynecol. Oncol., 131: 395-399.
CrossRef  |  PubMed  |  Direct Link  |  
46:   Signorelli, M., L. Guerra, L. Montanelli, C. Crivellaro and A. Buda et al., 2011. Preoperative staging of cervical cancer: Is 18-FDG-PET/CT really effective in patients with early stage disease? Gynecol. Oncol., 123: 236-240.
CrossRef  |  PubMed  |  
47:   Signorelli, M., R. Fruscio, A.A. Lissoni, C. Pirovano, P. Perego and C. Mangioni, 2008. Synchronous early-stage endometrial and ovarian cancer. Int. J. Gynaecol. Obstet., 102: 34-38.
CrossRef  |  PubMed  |  
48:   Signorelli, M., R. Fruscio, L. Ceppi, D. Vitobello and V. Chiappa et al., 2014. The role of pelvic and aortic lymphadenectomy at second look surgery in apparent early stage ovarian cancer after inadequate surgical staging followed by adjuvant chemotherapy. Gynecol. Oncol. 10.1016/j.ygyno.2014.01.001.
CrossRef  |  
49:   Signorelli, M., R. Fruscio, T. Dell'Anna, A. Buda, D. Giuliani, L. Ceppi and R. Milani, 2010. Lymphadenectomy in uterine low-grade endometrial stromal sarcoma: An analysis of 19 cases and a literature review. Int. J. Gynecol. Cancer, 20: 1363-1366.
CrossRef  |  PubMed  |  
50:   Signorelli, M., V. Chiappa, L. Minig, R. Fruscio and P. Perego et al., 2009. Platinum, anthracycline and alkylating agent-based chemotherapy for ovarian carcinosarcoma. Int. J. Gynecol. Cancer, 19: 1142-1146.
CrossRef  |  PubMed  |  
51:   Silini, A., C. Ghilardi, S. Figini, F. Sangalli and R. Fruscio et al., 2012. Regulator of G-protein signaling 5 (RGS5) protein: A novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. Cell Mol. Life Sci., 69: 1167-1178.
CrossRef  |  PubMed  |  
52:   Sottani, C., T. Colombo, M. Zucchetti, R. Fruscio, M. D'Incalci and C. Minoia, 2001. High-performance liquid chromatography/tandem mass spectrometry for the quantitative analysis of a novel taxane derivative (BAY59-8862) in biological samples and characterisation of its metabolic profile in rat bile samples. Rapid Commun. Mass Spectrom., 15: 1807-1816.
CrossRef  |  
53:   Timmerman, D., B. Van Calster, A.C. Testa, S. Guerriero and D. Fischerova et al., 2010. Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: A temporal and external validation study by the IOTA group. Ultrasound Obstetrics Gynecol., 36: 226-234.
CrossRef  |  
54:   Timmerman, D., L. Ameye, D. Fischerova, E. Epstein and G.B. Melis et al., 2010. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: Prospective validation by IOTA group. Br. Med. J., Vol. 341. .
Direct Link  |  
55:   Trio, C., D. Recalcati, F. Sina and R. Fruscio, 2010. Intrauterine fallopian tube incarceration after vacuum aspiration for pregnancy termination. Int. J. Gynaecol. Obstet, 108: 157-158.
CrossRef  |  PubMed  |  
56:   Valentin L., L. Ameye, L. Savelli, R. Fruscio and F.P. Leone et al., 2013. Unilocular adnexal cysts with papillary projections but no other solid components: Is there a diagnostic method that can classify them reliably as benign or malignant before surgery? Ultrasound Obstet. Gynecol., 41: 570-581.
CrossRef  |  PubMed  |  Direct Link  |  
57:   Valentin, L., L. Ameye, D. Franchi, S. Guerriero, D. Jurkovic et al., 2013. Risk of malignancy in unilocular cysts: A study of 1148 adnexal masses classified as unilocular cysts at transvaginal ultrasound and review of the literature. Ultrasound Obstet. Gynecol., 41: 80-89.
CrossRef  |  PubMed  |  Direct Link  |  
58:   Valentin, L., L. Ameye, L. Savelli, R. Fruscio and F.P.G. Leone et al., 2011. Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray‐scale and Doppler ultrasound findings: Logistic regression models do not help. Ultrasound Obstetrics Gynecol., 38: 456-465.
CrossRef  |  
59:   Van Holsbeke, C.D., B. Van Calster, T. Bourne, S. Ajossa, A.C. Testa and S. Guerriero et al., 2012. External validation of diagnostic models to estimate the risk of malignancy in adnexal masses. Clin. Can. Res., 18: 815-825.
PubMed  |  
60:   Vecchione, F., R. Fruscio, T. Dell'Anna, A. Garbi, R. Garcia Parra, S. Corso and A.A. Lissoni, 2007. A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer. Int. J. Gynecol. Cancer, 17: 367-372.
CrossRef  |  
61:   Vizza, E., A. Pellegrino, R. Milani, R. Fruscio and E. Baiocco et al., 2011. Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in locally advanced stage IB2-IIB cervical cancer patients after neoadjuvant chemotherapy. Eur. J. Surgical Oncol., 37: 364-369.
CrossRef  |  
62:   Zaffaroni, M., R. Frapolli, T. Colombo, R. Fruscio and E. Bombardelli et al., 2002. High-performance liquid chromatographic assay for the determination of the novel C-Seco-taxane derivative (IDN 5390) in mouse plasma. J. Chromatogr. B, 780: 93-98.
CrossRef  |  Direct Link  |